research
An Antidepressant Clears a Long-COVID Trial
In a 399-person randomized trial, fluvoxamine reduced persistent fatigue and improved reported quality of life.
Summary
In a 399-person randomized trial, fluvoxamine reduced persistent fatigue and improved reported quality of life.
The REVIVE-TOGETHER trial enrolled 399 adults in Brazil with fatigue lasting at least 90 days after confirmed SARS-CoV-2 infection. Participants received fluvoxamine, metformin, or placebo for 60 days. Fluvoxamine outperformed placebo on fatigue and quality-of-life measures, while metformin did not improve established fatigue. The adaptive trial offers evidence for one symptom in one study population; the authors say further work must identify who benefits and how the drug fits into broader long-COVID care.
Why it matters
In a 399-person randomized trial, fluvoxamine reduced persistent fatigue and improved reported quality of life.
Limits and context
- Fluvoxamine outperformed placebo on fatigue and quality-of-life measures, while metformin did not improve established fatigue.
Key claims
In a 399-person randomized trial, fluvoxamine reduced persistent fatigue and improved reported quality of life.
Qualification: Fluvoxamine outperformed placebo on fatigue and quality-of-life measures, while metformin did not improve established fatigue.
Evidence: source-2026-07-19-003
Sources
- McMaster University via ScienceDaily: Fluvoxamine and long-COVID fatigueMcMaster University via ScienceDaily · secondary reporting
Corrections
No corrections have been recorded for this story.